Trial Profile
A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Relapse or Refractory Acute Lymphoblastic Leukemia and Lymphoma Subjects
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 07 Feb 2023
Price :
$35
*
At a glance
- Drugs BinD 19 (Primary)
- Indications B-cell lymphoma; Follicular lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors Shenzhen BinDeBio
- 03 Feb 2021 Planned End Date changed from 30 Dec 2020 to 30 Dec 2021.
- 03 Feb 2021 Planned primary completion date changed from 30 Jun 2020 to 30 May 2021.
- 10 Dec 2019 Status changed from recruiting to active, no longer recruiting.